Double awards for Elypta co-founder Francesco Gatto

Elypta co-founder Francesco Gatto received two prestigious awards in May for his ground-breaking research at Chalmers and Elypta, aiming to develop the first metabolism-based liquid biopsy for early detection of cancer. He was included in the renowned publication Genetic Engineering News list of Top 10 Under 40 of rising stars in biotech and was also awarded the Karin Markides Innovation prize for 2019.

2,35 million euro from EU Horizon 2020

Earlier this year we could report that Elypta received 2,35 million euro from EU Horizon to bring their cancer treatment to clinical trials. Read more below.

Elypta vinnare i EUs Horizon 2020 utlysning – 24 mkr för att ta ett nytt cancer-test till marknaden

Elypta is a portfolio company to Chalmers Ventures